These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30274977)

  • 1. Redesigning Prostate Cancer Screening Strategies to Reduce Overdiagnosis.
    Vickers AJ
    Clin Chem; 2019 Jan; 65(1):39-41. PubMed ID: 30274977
    [No Abstract]   [Full Text] [Related]  

  • 2. The need for active surveillance for low risk prostate cancer.
    Drost FH; Roobol MJ
    Expert Rev Anticancer Ther; 2017 Jun; 17(6):487-489. PubMed ID: 28406334
    [No Abstract]   [Full Text] [Related]  

  • 3. [Current aspects of prostate cancer screening].
    Jalón Monzón A; Escaf Barmadah S; Viña Alonso LM; Jalón Monzón M
    Semergen; 2017; 43(5):387-393. PubMed ID: 27562331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer Testing.
    Eklund M; Nordström T; Aly M; Adolfsson J; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Presti JC; StLezin M; Clements M; Egevad L; Grönberg H
    Eur Urol Focus; 2018 Sep; 4(5):707-710. PubMed ID: 28753803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and overdiagnosis of prostate cancer: a personal view.
    Tam PC
    Hong Kong Med J; 2012 Dec; 18(6):456-8. PubMed ID: 23223644
    [No Abstract]   [Full Text] [Related]  

  • 6. [Improved prostate cancer diagnostics with a struc-tured pathway including the Stockholm3 test and MRI--targeted biopsies - experiences from Capio S:t Göran Prostate Cancer Center].
    Bergman M; Hjälm Ericsson M; Jäderling F; Meurling E; Thorstensson A; Nordström T; Henrik G
    Lakartidningen; 2018 Oct; 115():. PubMed ID: 30351440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis.
    Horton RH; Dunlop MG; Houlston RS; Lucassen A; McCartney M; McNeill A; Sud A
    Br J Cancer; 2023 Jan; 128(1):1-2. PubMed ID: 36443602
    [No Abstract]   [Full Text] [Related]  

  • 8. Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit.
    Vickers A; O'Brien F; Montorsi F; Galvin D; Bratt O; Carlsson S; Catto JW; Krilaviciute A; Philbin M; Albers P
    BMJ; 2023 May; 381():e071082. PubMed ID: 37197772
    [No Abstract]   [Full Text] [Related]  

  • 9. Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 Model.
    Nordström T; Grönberg H; Adolfsson J; Egevad L; Aly M; Eklund M
    Eur Urol Focus; 2018 Apr; 4(3):385-387. PubMed ID: 28753831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to: Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis (BJC-LT3342090).
    Green HD; Merriel SWD; Oram RA; Ruth KS; Tyrrell J; Jones SE; Thirlwell C; Weedon MN; Bailey SER
    Br J Cancer; 2023 Feb; 128(4):487-488. PubMed ID: 36536048
    [No Abstract]   [Full Text] [Related]  

  • 11. Reconsidering Prostate Cancer Mortality - The Future of PSA Screening.
    Welch HG; Albertsen PC
    N Engl J Med; 2020 Apr; 382(16):1557-1563. PubMed ID: 32294352
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostate-specific antigen dynamics and prostate cancer diagnosis.
    Bartoletti R
    Eur Urol; 2009 Nov; 56(5):761-2; discussion 763. PubMed ID: 19665286
    [No Abstract]   [Full Text] [Related]  

  • 13. Summaries for patients. Screening smarter, not harder, for prostate cancer.
    Ann Intern Med; 2013 Feb; 158(3):I-30. PubMed ID: 23381056
    [No Abstract]   [Full Text] [Related]  

  • 14. [Prostate cancer screening: Reasons of controversy].
    Delporte G; Villers A; Penel N
    Bull Cancer; 2018 Dec; 105(12):1111-1118. PubMed ID: 30458966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer screening: the need for problem-solving that puts men's interests first.
    Holmberg L
    Eur Urol; 2009 Jul; 56(1):34-7. PubMed ID: 19394132
    [No Abstract]   [Full Text] [Related]  

  • 16. Reliability of PSA testing remains unclear.
    Ciatto S
    BMJ; 2003 Sep; 327(7417):750. PubMed ID: 14512493
    [No Abstract]   [Full Text] [Related]  

  • 17. The story of the European Randomized Study of Screening for Prostate Cancer.
    Schröder FH; Denis LJ; Roobol M; Nelen V; Auvinen A; Tammela T; Villers A; Rebillard X; Ciatto S; Zappa M; Berenguer A; Paez A; Hugosson J; Lodding P; Recker F; Kwiatkowski M; Kirkels WJ;
    BJU Int; 2003 Dec; 92 Suppl 2():1-13. PubMed ID: 14983946
    [No Abstract]   [Full Text] [Related]  

  • 18. Prostate-specific antigen (PSA) should drive doing prostate biopsies.
    Loeb S; Catalona WJ
    Urol Oncol; 2012; 30(1):1-2. PubMed ID: 21458316
    [No Abstract]   [Full Text] [Related]  

  • 19. [Not Available].
    Aktuelle Urol; 2014 Nov; 45(6):433. PubMed ID: 25514772
    [No Abstract]   [Full Text] [Related]  

  • 20. Prostate Cancer Screening and the Associated Controversy.
    Tabayoyong W; Abouassaly R
    Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.